KSSP supports distribution of generic drugs for SMA patients in Keralam
The Kerala Sastra Sahitya Parishad (KSSP) has endorsed the Kerala government's decision to provide generic Risdiplam for Spinal Muscular Atrophy (SMA) patients. This move has sparked controversy among parents who prefer the branded version of the medication.
Why it matters
The debate underscores the tension between cost-effective public health policy and patient access to preferred medical treatments for rare diseases.
KSSP supports distribution of generic drugs for SMA patients in Keralam left This image is used for representational purpose only. Getty Images/iStockphoto Getty Images/iStockphoto https://th-i.thgim.com/public/incoming/emandu/article71622825.ece/alternates/FREE_1200/iStock-2247959060.jpg Andrzej Rostek SMA, spinal muscular atrophy. Health concept. Text on white blocks. Blue background, stethoscope. Incurable diseases. Copy space. Close up Kerala Sastra Sahitya Parishad president C. Ramakrishnan and general secretary V. Manoj Kumar said that access to this medication is crucial for improving the quality of life and life expectancy of patients Kozhikode The Kerala Sastra Sahitya Parishad (KSSP) has supported the Kerala Health Department’s decision to provide a low-cost generic version of the drug Risdiplam to patients afflicted with Spinal Muscular Atrophy (SMA), a rare and threatening genetic disorder that causes progressive muscle weakness. What is the controversy over the spinal muscular atrophy drug in Keralam? Explained What is the controversy over the spinal muscular atrophy drug in Keralam?
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in